Basis: Evaluating Sirtuin Supplements To Benefit Elderly Trauma Patients (BES2T BET)

Recruiting
99 years or below
All
Phase 1
48 participants needed
1 Location

Brief description of study

Adults 65 and older are more likely to have significant injuries from minor things like falls. They can have problems regaining strength due to sarcopenia (loss of muscle tissue as part of natural aging process). Nicotinamide riboside/pterstilbene (Basis) is commercially available nutraceutical. This randomized, double blind placebo controlled trial will investigate the impact of Basis on the functional recovery of elderly patients (65 years or older) admitted to the trauma service post-injury. Basis (or placebo) will be taken orally for 90 days. Bioactivity will be tracked daily. Functional, cognitive, and biochemical assays will be assessed at 24 hrs, discharge, 6 weeks, and then at 3 months post injury. See Protocol Section 4.1 for Inclusion and Exclusion Criteria

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: trauma, Recovery of Function
  • Age: 99 years or below
  • Gender: All
Updated on 19 Feb 2024. Study ID: 829947

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.